RxDoctor Payments Data

Erick Chan, MD

Gastroenterology · Palo Alto, CANPI 1497817746

Payments from drug & device makers

$5,558in general payments, 2019–2025

Across 17 payments — averaging $326.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$5K
  • Boston Scientific$200
  • GSK$107
  • Lilly USA, LLC$68
  • Novo Nordisk$32
  • Mauna Kea Technologies, Inc.$29
  • plus $47 from 2 others

What the payments were for

  • Consulting fees$4,66084%
  • Travel & lodging$2745%
  • Food & beverage$62411%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,558 in reported general payments places this provider in the 65th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$179,445
Medicare patients
583
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide43$97,493
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates284$18,948
LinzessLinaclotide24$16,767
Ursodiol46$7,310
Tenofovir Disoproxil Fumarate30$7,007
Entecavir40$5,102
Omeprazole107$1,036
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg31$620
Pantoprazole Sodium21$395
Famotidine15$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$5,074$97,49343 claims
AbbVieLinzess$27$16,76724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →